[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356574-105":59,"doc-detail-356574-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","compound-library-screening-identified-cladribine-as-a-novel-radiosensitizer-for-prostate-cancer","Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer","","Radiation therapy effectively treats prostate cancer, but tumor recurrence remains a clinical challenge, highlighting the need for strategies to enhance radiosensitivity. This study built a high-throughput drug repurposing screening platform to identify radiosensitizers from U.S. FDA-approved compounds. A luciferase-based workflow screened 1134 compounds in LNCaP cells, followed by radiation-dose and concentration testing to pinpoint candidates. Cladribine showed the strongest radiosensitizing activity, enhanced radiation-induced cytotoxicity across prostate cancer cell lines, blocked DNA double-strand break repair, and was validated in vivo using xenograft models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/compound-library-screening-identified-cladribine-as-a-novel-radiosensitizer-for-prostate-cancer/356574/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/compound-library-screening-identified-cladribine-as-a-novel-radiosensitizer-for-prostate-cancer/356574.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the goal of the study on cladribine?","Question",{"text":112,"@type":113},"The study aims to identify clinically relevant radiosensitizers for prostate cancer and determine whether cladribine can enhance the effects of radiation therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the radiosensitizer screening performed?",{"text":117,"@type":113},"A high-throughput luciferase-based platform screened 1134 FDA-approved compounds at two concentrations using LNCaP cells, followed by secondary testing across radiation doses and multiple drug concentrations.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports cladribine as the most potent radiosensitizer?",{"text":121,"@type":113},"Cladribine increased radiation-induced cytotoxicity in multiple prostate cancer cell lines, prevented repair of radiation-induced DNA double-strand breaks as shown by elevated γH2AX, and demonstrated radiosensitizing effects in vivo xenograft models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356574,1790322556,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nCompound Library Screening Identified Cladribine asa Novel Radiosensitizer for Prostate Cancer  \nToshiki Oka1  | Koji Hatano1  | Shohei Katsuki2 | Tomohiro Kanaki1 | Shunsuke Inoguchi1 | Masaru Tani1  | Akihiro Yoshimura1 | Yuki Horibe1 | Yutong Liu1 | Nesrine Sassi1 | Yohei Okuda1 | Akinaru Yamamoto1  |  \nToshihiro Uemura1 | Gaku Yamamichi1 | Yu Ishizuya1 | Takuji Hayashi1 | Yoshiyuki Yamamoto1 | Taigo Kato1  | Atsunari Kawashima1  | Keisuke Tamari3 | Bangzhong Lin4 | Akiyoshi Tani4 | Kazutake Tsujikawa4 | Yutaka Takahashi2 | Kazuhiko Ogawa3 | Shawn E. Lupold5 | Norio Nonomura1   \n1Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan | 2Department of Medical Physics and Engineering, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan | 3Department of Radiation Oncology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan | 4Center for Supporting Drug Discovery and Life Science Research, The University of Osaka Graduate School of Pharmaceutical Science, Suita, Osaka, Japan | 5The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University Schoolof Medicine, Baltimore, Maryland, USA  \nCorrespondence: Koji Hatano ([koj.hatan@gmail.com](koj.hatan@gmail.com))  \nReceived: 13 August 2025 | Revised: 30 December 2025 | Accepted: 12 January 2026  \nKeywords: cladribine | compound library screening | prostate cancer | radiation | radiosensitizer  \nABSTRACT  \nRadiation therapy effectively treats prostate cancer, but tumor recurrence remains a clinical challenge, highlighting the need for strategies to enhance radiosensitivity. In this study, we developed a simple, high-throughput drug repurposing screening platform to find radiosensitizers from compounds approved by the U.S. Food and Drug Administration. A library of 1134 compounds was systematically screened at two concentrations (0.2 and 2 μM) using LNCaP cells stably expressing Metridia luciferase, allowing highly sensitive and quantitative assessment of cell viability through luciferase activity in culture supernatants. In the primary screening, 8 and 12 candidate radiosensitizers were identified at 0.2 μM and 2 μM, respectively. In the secondary screening, 19 compounds were evaluated at two radiation doses (4 Gy and 6 Gy) and six drug concentrations, identifying 5 radiation-sensitizing candidate compounds. Through this stepwise screening approach, cladribine was identified as the most potent radiosensitizer. Cladribine increased radiation-induced cytotoxicity in multiple prostate cancer cell lines (22Rv1, DU145, and PC3), with dose-modifying factors of 1.46, 1.55, and 1.43, respectively, based on the radiation dose needed to achieve 90% cell death. Mechanistically, cladribine prevented the repair of radiation-induced DNA double-strand breaks, shown by increased γH2AX levels. Importantly, its radiosensitizing effect was further confirmed in vivo using 22Rv1 and DU145 xenograft models. This study demonstrates that a luciferase-based high-throughput drug repurposing platform is useful for identifying clinically relevant radiosensitizers, revealing that cladribine is a promising candidate for further translational research in prostate cancer radiotherapy.  \n\n| Abbreviations: 2-CdATP, 2-chlorodeoxyadenosine triphosphate; AR, androgen receptor; BSA, bovine serum albumin; CRPC, castration-resistant prostate cancer; DMF, dose modifying factor; DMSO, dimethyl sulfoxide; dNTP, deoxynucleoside triphosphate; DSB, DNA double-strand break; FDA, Food and Drug Administration; HTS, high-throughput screening; IR, ionizing radiation; MLuc, metridia luciferase; MTS3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) - 2H-tetrazolium; MTT, 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PCa, prostate cancer; Ra-223, radium-223 chloride. |\n| --- |\n| This is an open access article under the terms of t","cbCaihLBqOvt0gHr","https://ap.wps.com/l/cbCaihLBqOvt0gHr","pdf",4689467,12,"English","# Introduction\n## Radiation therapy limitations in prostate cancer\n## Need for novel radiosensitizing strategies","[{\"question\":\"What is the goal of the study on cladribine?\",\"answer\":\"The study aims to identify clinically relevant radiosensitizers for prostate cancer and determine whether cladribine can enhance the effects of radiation therapy.\"},{\"question\":\"How was the radiosensitizer screening performed?\",\"answer\":\"A high-throughput luciferase-based platform screened 1134 FDA-approved compounds at two concentrations using LNCaP cells, followed by secondary testing across radiation doses and multiple drug concentrations.\"},{\"question\":\"What evidence supports cladribine as the most potent radiosensitizer?\",\"answer\":\"Cladribine increased radiation-induced cytotoxicity in multiple prostate cancer cell lines, prevented repair of radiation-induced DNA double-strand breaks as shown by elevated γH2AX, and demonstrated radiosensitizing effects in vivo xenograft models.\"}]","Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer | PDF",1790126023,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57b819280411a17c6e139a0c8c3023b6.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a8b97d21e44c746b2e8783b7226bfa3.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1c46d54b9419eda48a9df7c33f7b7ca.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c8af0182d83be621c00e7e4623a65cf.webp",980,1287]